These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11984088)

  • 1. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study.
    Recchia F; Sica G; De Filippis S; Saggio G; Rosselli M; Rea S
    Anticancer Drugs; 2002 Apr; 13(4):417-24. PubMed ID: 11984088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
    Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
    Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
    Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
    J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
    Michaud LB; Buzdar AU
    Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
    Jonat W
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
    Sverrisdottir A; Nystedt M; Johansson H; Fornander T
    Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
    Jakesz R; Hausmaninger H; Kubista E; Gnant M; Menzel C; Bauernhofer T; Seifert M; Haider K; Mlineritsch B; Steindorfer P; Kwasny W; Fridrik M; Steger G; Wette V; Samonigg H;
    J Clin Oncol; 2002 Dec; 20(24):4621-7. PubMed ID: 12488405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
    Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
    Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of goserelin in the treatment of breast cancer.
    Rody A; Loibl S; von Minckwitz G; Kaufmann M
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).
    Urruticoechea A; Arnedos M; Walsh G; Dowsett M; Smith IE
    Breast Cancer Res Treat; 2008 Aug; 110(3):411-6. PubMed ID: 17851753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer--another step forward.
    Pater JL; Parulekar WR
    J Natl Cancer Inst; 2003 Dec; 95(24):1811-2. PubMed ID: 14679143
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients.
    Del Mastro L; Catzeddu T; Boni L; Bell C; Sertoli MR; Bighin C; Clavarezza M; Testa D; Venturini M
    Ann Oncol; 2006 Jan; 17(1):74-8. PubMed ID: 16254024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
    J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
    Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
    Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
    J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of ovarian ablation with goserelin in a pre-menopausal breast cancer patient resulting in pregnancy: a case report and review of the literature.
    Hill N; Madarnas Y
    Breast Cancer Res Treat; 2011 Aug; 129(1):265-8. PubMed ID: 21541703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
    Boccardo F; Rubagotti A; Amoroso D; Mesiti M; Romeo D; Sismondi P; Giai M; Genta F; Pacini P; Distante V; Bolognesi A; Aldrighetti D; Farris A
    J Clin Oncol; 2000 Jul; 18(14):2718-27. PubMed ID: 10894871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
    Pritchard KI
    Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.